Protagonist Therapeutics (PTGX) Depreciation & Amortization (CF) (2015 - 2026)

Protagonist Therapeutics has disclosed Depreciation & Amortization (CF) across 12 years of filings, most recently posting $407000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $407000.0, up 70.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (up 74.67% YoY), and the FY2025 annual result was $1.3 million, up 54.96% from the prior year.
• Depreciation & Amortization (CF) came in at $407000.0 for Q1 2026 at Protagonist Therapeutics, up from $376000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $407000.0 in Q1 2026 to a low of $118000.0 in Q4 2024.
• The 5-year median for Depreciation & Amortization (CF) is $248000.0 (2023), against an average of $266117.6.
• Across the five-year window, Depreciation & Amortization (CF) slumped 52.42% in 2024 and surged 218.64% in 2025, its largest moves.
• Protagonist Therapeutics' Depreciation & Amortization (CF) stood at $256000.0 in 2022, then retreated by 3.12% to $248000.0 in 2023, then plunged by 52.42% to $118000.0 in 2024, then soared by 218.64% to $376000.0 in 2025, then climbed by 8.24% to $407000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $407000.0 (Q1 2026), $376000.0 (Q4 2025), and $361000.0 (Q3 2025), per Business Quant data.